Literature DB >> 2404343

Recent developments in the radiolabeling of antibodies with iodine, indium, and technetium.

D J Hnatowich1.   

Abstract

The use of radiolabeled antibodies for tumor detection and therapy has provided some striking successes despite unfavorable tumor-to-normal tissue radioactivity ratios due, in part, to the accumulation of the label in normal tissues. One approach, which has been and is still under consideration to reduce unwanted background levels, is the improvement of ways in which radiolabels are attached to antibody, especially with the goal of increasing in vivo stability. Although these improvements have occurred throughout the history of this field, important developments have recently been reported in the labeling of antibodies with three radiolabels, namely radioiodine, 111In, and 99mTc. Thus, antibodies may now be labeled with radioisotopes of iodine in ways that minimize the extent of in vivo dehalogenation leading to thyroid, stomach, and gut radioactivity uptake. Newer and stronger chelates for 111In have been developed in the hope that their use would result in lower radioactivity levels in the liver. Finally, newer methods, both direct and indirect, for the attachment of 99mTc to antibodies have been developed and are now being clinically tested. Although these developments have taken place only recently and the in vivo behavior of labels attached in these ways have not yet been fully characterized, it is possible to make tentative conclusions regarding their impact. Thus, the use of stably radioiodinated antibodies appears to have resulted in modest improvements in patient images. In contrast, the use of stable chelates for labeling antibodies with 111In may have had no appreciable effect on liver radioactivity levels. The use of antibodies radiolabeled with 99mTc, especially via the newer direct labeling methods, are providing superior images in patients with low radioactivity levels in organs such as liver. However, it must still be established whether the short physical half-life of 99mTc lowers sensitivities and specificities of detection relative to other labels.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2404343     DOI: 10.1016/s0001-2998(05)80178-3

Source DB:  PubMed          Journal:  Semin Nucl Med        ISSN: 0001-2998            Impact factor:   4.446


  14 in total

Review 1.  Immunoscintigraphy for cancer detection: "a thousand ills require a thousand cures".

Authors:  S H de Bie; T C Ferreira; E K Pauwels; F J Cleton
Journal:  J Cancer Res Clin Oncol       Date:  1992       Impact factor: 4.553

Review 2.  Radiopharmaceuticals: state of the art.

Authors:  A M Verbruggen
Journal:  Eur J Nucl Med       Date:  1990

3.  Characterization of 99mTc-labeled cytokine ligands for inflammation imaging via TNF and IL-1 pathways.

Authors:  Zhonglin Liu; Leonie Wyffels; Christy Barber; Li Wan; Hua Xu; Mizhou M Hui; Lars R Furenlid; James M Woolfenden
Journal:  Nucl Med Biol       Date:  2012-06-28       Impact factor: 2.408

Review 4.  Micro-imaging of amyloid in mice.

Authors:  Jonathan S Wall; Michael J Paulus; Shaun Gleason; Jens Gregor; Alan Solomon; Stephen J Kennel
Journal:  Methods Enzymol       Date:  2006       Impact factor: 1.600

5.  Improved cancer therapy and molecular imaging with multivalent, multispecific antibodies.

Authors:  Robert M Sharkey; Edmund A Rossi; Chien-Hsing Chang; David M Goldenberg
Journal:  Cancer Biother Radiopharm       Date:  2010-02       Impact factor: 3.099

6.  Radioimmunolocalization of human pancreatic carcinoma xenograft by 99mTc-labeled YPC3 monoclonal antibody.

Authors:  Q Chen; S Yuan
Journal:  J Cancer Res Clin Oncol       Date:  1994       Impact factor: 4.553

7.  Radioimmunoscintigraphy of colorectal cancer with technetium-99m-labeled murine anti-carcinoembryonic antigen monoclonal antibody in athymic nude mice.

Authors:  N Watanabe; N Oriuchi; S Sugiyama; M Kuroki; Y Matsuoka
Journal:  Ann Nucl Med       Date:  1994-02       Impact factor: 2.668

8.  Inhibition of the hepatocyte uptake of radiolabelled monoclonal antibodies by chelating agents.

Authors:  B R Davidson; P B Boulos; J B Porter
Journal:  Eur J Nucl Med       Date:  1990

9.  SPECT/CT Imaging of Mycobacterium tuberculosis Infection with [125I]anti-C3d mAb.

Authors:  Catherine A Foss; Liudmila Kulik; Alvaro A Ordonez; Sanjay K Jain; V Michael Holers; Joshua M Thurman; Martin G Pomper
Journal:  Mol Imaging Biol       Date:  2019-06       Impact factor: 3.488

10.  Molecular SPECT Imaging: An Overview.

Authors:  Magdy M Khalil; Jordi L Tremoleda; Tamer B Bayomy; Willy Gsell
Journal:  Int J Mol Imaging       Date:  2011-04-05
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.